Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00130286 · ClinicalTrials.gov registry record · Phase 1
Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance
A Phase 1 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 1
- Development phase
- 77
- Enrollment target
NCT00130286 is a Phase 1 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 77 participants.
The verdict
NCT00130286, a Phase 1 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 77 participants
- Enrollment target
Study Summary
The purpose of the study is to determine if the combination of recombinant human growth hormone plus rosiglitazone (an insulin-sensitizing drug) is safe and more effective than either drug alone (or no active therapy) for the treatment of fat accumulation in people with HIV infection and insulin resistance.
Interventions
- DRUG Rosiglitazone
- DRUG Recombinant human growth hormone + rosiglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2005-03 |
| Est. Completion | 2010-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00130286
The ClinicalTrials.gov registry entry for NCT00130286 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rosiglitazone is the first listed.
NCT00130286 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00130286 about?
NCT00130286 is a clinical study titled "Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance". The purpose of the study is to determine if the combination of recombinant human growth hormone plus rosiglitazone (an insulin-sensitizing drug) is safe and more effective than either drug alone (or no active therapy) for the treatment of fat accumulation in people with HIV infection and insulin res...
What is the current status of trial NCT00130286?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 77 participants. The study started on 2005-03. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00130286?
The interventions under investigation include: Rosiglitazone (DRUG), Recombinant human growth hormone + rosiglitazone (DRUG).
Who is sponsoring clinical trial NCT00130286?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.